PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study to Assess the Pharmacokinetics, Safety and Tolerability of Aztreonam-Avibactam in Healthy Chinese Participants.
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT04973826
- Locations
- 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China
Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules
- Conditions
- HypertensionHeart Failure
- Interventions
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 72
- Registration Number
- NCT04967443
- Locations
- 🇺🇸
Clinical Trials of Texas, LLC, San Antonio, Texas, United States
Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants
- Conditions
- Healthy Participant
- Interventions
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT04962022
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir
- Conditions
- Healthy Participant
- Interventions
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT04962230
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2246
- Registration Number
- NCT04960202
- Locations
- 🇺🇸
Cahaba Research Inc, Pelham, Alabama, United States
🇺🇸The Institute for Liver Health dba Arizona Clinical Trials, Tucson, Arizona, United States
🇺🇸Hope Clinical Research, Canoga Park, California, United States
Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 350
- Registration Number
- NCT04937660
- Locations
- 🇪🇬
Dar El Salam Oncology Hospital, Cairo, Egypt
🇪🇬National Cancer Institute, Cairo, Egypt
🇶🇦Hamad Medical Corporation, Doha, Qatar
A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
- Conditions
- Sickle Cell DiseaseVaso-occlusive Pain Episode in Sickle Cell DiseaseVaso-occlusive Crisis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 243
- Registration Number
- NCT04935879
- Locations
- 🇺🇸
UCI Center for clinical research, Orange, California, United States
🇺🇸University of South Alabama Children's and Women's Hospital, Mobile, Alabama, United States
🇺🇸University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 262
- Registration Number
- NCT04930445
- Locations
- 🇺🇸
Newark Beth Israel Medical Center, Newark, New Jersey, United States
🇺🇸University of South Alabama, Mobile, Alabama, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
Retrospective Real World Oxbryta® Data Collection and Analysis Study
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 216
- Registration Number
- NCT04930328
- Locations
- 🇺🇸
Rutgers Robert Wood Johnson Medical School Pediatric Clinical Research Center, New Brunswick, New Jersey, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
- Conditions
- Sickle Cell DiseaseVaso-occlusive Pain Episode in Sickle Cell DiseaseVaso-occlusive Crisis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 72
- Registration Number
- NCT04927247
- Locations
- 🇺🇸
University of South Alabama Children's and Women's Hospital, Mobile, Alabama, United States
🇺🇸University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸Strada Patient Care Center, Mobile, Alabama, United States